118 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
LGND Ligand Pharmaceuticals Incorporated $153.81 $3.25B Uptrend
Article Searches
Your Daily Pharma Scoop: Dynavax Achieves Major Milestone, GW Pharmaceuticals GWP42006 Fails, Sangamo Signs Deal With Gilead's Kite Unit https://seekingalpha.com/article/4149469-daily-pharma-scoop-dynavax-achieves-major-milestone-gw-pharmaceuticals-gwp42006-fails-sangamo?source=feed_sector_healthcare Feb 23, 2018 - Dynavax’s commercialization efforts with HEPLISAV-B get a boost.GW Pharmaceuticals’ GWP42006 fails in proof-of-concept study.Sangamo inks a deal with Gilead’s Kite Pharma unit.
Ligand (LGND) Q4 Earnings & Revenues Top, 2018 View Solid http://www.zacks.com/stock/news/293349/ligand-lgnd-q4-earnings-revenues-top-2018-view-solid?cid=CS-ZC-FT-293349 Feb 22, 2018 - Ligand's (LGND) earnings and revenues beat estimates. The top line also rises year over year owing to higher royalty benefits. The company provides a strong 2018 guidance.
Ligand Pharmaceuticals' (LGND) CEO John Higgins on Q4 2017 Results - Earnings Call Transcript https://seekingalpha.com/article/4149224-ligand-pharmaceuticals-lgnd-ceo-john-higgins-q4-2017-results-earnings-call-transcript?source=feed_sector_healthcare Feb 21, 2018 - Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) Q4 2017 Earnings Conference Call February 21, 2018, 16:30 ET Executives Todd Pettingill - IR John Higgins - CEO and Executive Director Matthew Foehr - Presid
What's in Store for Ligand (LGND) This Earnings Season? http://www.zacks.com/stock/news/292881/whats-in-store-for-ligand-lgnd-this-earnings-season?cid=CS-ZC-FT-292881 Feb 19, 2018 - Ligand's (LGND) Captisol formulation technology aids the company to form partnerships with several leading healthcare companies. This in turn might drive the stock in Q4.
Ligand Pharma Is A Short https://seekingalpha.com/article/4141370-ligand-pharma-short?source=feed_tag_short_ideas Jan 30, 2018 - LGND is not a diversified biopharma technology specialist, but a one product commodity middleman.A direct Captisol substitute is available from a fully integrated, high-quality supplier.Ligand does no
Daily Insider Ratings Round Up 1/26/18: TEI, CPAH, OPK, CNBKA https://seekingalpha.com/article/4140780-daily-insider-ratings-round-1-26-18-tei-cpah-opk-cnbka?source=feed_all_articles Jan 28, 2018 - Tables of the top insider purchases and sales filed with the SEC on 1/26/18, based on dollar value. Dollar values often do not equate with significance when it comes to insider trades. Proprietary Ins
Your Daily Pharma Scoop: Progenics Gaining Momentum, Nymox Data, Ligand Outlicenses Platform https://seekingalpha.com/article/4139333-daily-pharma-scoop-progenics-gaining-momentum-nymox-data-ligand-outlicenses-platform?source=feed_sector_healthcare Jan 24, 2018 - Progenics has made a solid start to the year. Nymox announced positive long-term data on lead drug fexapotide. Ligand out-licensed OmniAb antibody discovery platform to Ferring Pharmaceuticals.
Your Daily Pharma Scoop: Lipocine's Gloomy Future, Puma Labeling Change, Concert's Mixed Day https://seekingalpha.com/article/4137276-daily-pharma-scoop-lipocines-gloomy-future-puma-labeling-change-concerts-mixed-day?source=feed_sector_healthcare Jan 13, 2018 - With the TLANDO setback, the outlook for Lipocine is gloomy.Puma plans to modify labeling in its European marketing application for its breast cancer candidate neratinib.Concert had a mixed day with t
Ligand (LGND) Inks Deal With Glenmark for OmniAb Platform http://www.zacks.com/stock/news/288701/ligand-lgnd-inks-deal-with-glenmark-for-omniab-platform?cid=CS-ZC-FT-288701 Jan 12, 2018 - Ligand (LGND) enters into a worldwide license agreement with Glenmark for OmniAb platform.
Viking's VK2809: A Question Of Safety, Not Efficacy https://seekingalpha.com/article/4136028-vikings-vk2809-question-safety-efficacy?source=feed_sector_healthcare Jan 08, 2018 - Thyroid receptor agonists have long been known to substantially lower cholesterol.However, because of unintended consequences of raising thyroid hormones elsewhere in the body, they have, again and ag

Pages: 123456...12

Page 1>

Related Companies

Name Exchange Price Mkt Cap
TSRO TESARO, Inc. NASDAQ $60.74 $3.3B
LOXO Loxo Oncology, Inc. NASDAQ $113.91 $3.41B
PTLA Portola Pharmaceuticals, Inc. NASDAQ $45.82 $2.99B
GWPH GW Pharmaceuticals Plc NASDAQ $115.31 $2.93B
GBT Global Blood Therapeutics, Inc. NASDAQ $62.85 $2.91B
Sector: Health Care > Industry: Major Pharmaceuticals
DeepLinks for Ligand Pharmaceuticals Incorporated
LGND - Google Finance https://www.google.com/finance?q=LGND Industry related info and international coverage Summary News
LGND - Bloomberg http://www.bloomberg.com/research/stocks/snapshot/snapshot.asp?ticker=LGND Original news and commentary from Bloomberg Charts Financials with pensions Snapshot Earnings Transactions People Options